Advancing Change for Adverse Effects of Alcohol Consumption – SJP-001 Update

Advancing Change for Adverse Effects of Alcohol Consumption – SJP-001 Update

Sjp 001 Update

Two weeks ago, we received our patent for Canada, increasing the total number of countries covered by our intellectual property for this asset to 22. As many of you know, SJP-001 is a novel therapeutic aimed at reducing the adverse effects of alcohol consumption impacting the liver and producing the infamous hangover. Our clinical studies highlight these benefits. Additionally, recent research featured in this article has shown that alcohol consumption triggers an inflammatory response in the liver.

A recent double-blind randomized trial conducted by a research group in Boston revealed that daily low-dose aspirin (81 mg) for six months significantly reduced liver fat content and improved markers of hepatic inflammation and fibrosis in patients with metabolic-associated steatotic liver disease (MASLD) without cirrhosis, as presented at The Liver Meeting 2023. These findings suggest that low-dose aspirin could be a safe and well-tolerated treatment for MASLD, although larger and longer-term clinical trials are necessary for further validation. Additionally, alcohol-induced liver inflammation, mediated by pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-a) and interleukin-6 (IL-6), underscores the importance of understanding lifestyle factors in liver health, with implications extending to the management of hangover symptoms.

Our Phase 2 clinical trial for SJP-001, aimed at preventing the adverse effects of alcohol, is on track to commence once our sprint to $3M campaign is complete. We believe our innovative product reduces inflammation and tissue damage while reducing symptom intensity and duration.

Our licensing discussions with a large Japanese interest continue to progress in earnest. And, as mentioned in prior updates, our illustrious partnership with key strategic investor KVK-Tech has been working on engineering batches of SJP-001, which can be seen here:

We have what it takes to bring our vision to market:

  • Sen-Jam Pharmaceutical’s experienced team has led over $730M in previous exits.
  • Our partnership with KVK Tech has been instrumental in progressing the formulation and CMC work to align with Good Manufacturing Practices (GMP), ensuring product integrity and safety to meet FDA requirements (GMP batches highlighted above).
  • The commencement of this trial will reflect a massive inflection for Sen-Jam Pharmaceutical. We believe this asset will increase 3-5 times, delivering value to our shareholders. Sen-Jam Pharmaceutical’s SJP-001 will significantly impact the soon-to-be $6 billion annual hangover therapeutic market which is predicted to see a double-digit CAGR from now through 2030.

Here is a link to our new deck and a link to our narrated version (8 minutes).

Invest now and receive our Fractional Royalty Right incentive bonus while enjoying the benefits of our entire portfolio of assets.

Let’s do this…